In conclusion, our metagenomic and metabolomic study found the conspicuous associations between baseline microbiome/metabolome composition and the pathologic response in early‐stage NSCLC patients, which suggested a potential interventional strategy in improving the efficiency of neoadjuvant anti‐PD‐1 immunochemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.